Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
653.18(c) 651.88(c) 640.89(c) 646.95(c) 647.06 Last
540 043 762 045 666 652 440 841 499 236 Volume
+0.18% -0.20% -1.69% +0.95% +0.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 13 864 M - -
Net income 2021 6 822 M - -
Net cash position 2021 6 794 M - -
P/E ratio 2021 10,3x
Yield 2021 -
Sales 2022 12 209 M - -
Net income 2022 4 564 M - -
Net cash position 2022 9 282 M - -
P/E ratio 2022 15,0x
Yield 2022 -
Capitalization 67 262 M 67 262 M -
EV / Sales 2021 4,36x
EV / Sales 2022 4,75x
Nbr of Employees 9 635
Free-Float 82,0%
More Financials
Company
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,... 
Sector
Biotechnology & Medical Research
Calendar
09/27 | 09:20amPresentation
More about the company
Ratings of Regeneron Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about REGENERON PHARMACEUTICALS
10:08aREGENERON PHARMACEUTICALS : New dupixent (dupilumab) data in patients as young as six year..
AQ
09:42aWALL STREET STOCK EXCHANGE : Fed verdict is imminent
06:34aANALYST RECOMMENDATIONS : Blackstone, Burberry, FedEx, Hershey, Micron Technology...
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/21REGENERON PHARMACEUTICALS : BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to..
MT
09/21REGENERON PHARMACEUTICALS : New Dupixent« (dupilumab) Data in Patients as Young as Six Yea..
PR
09/20REGENERON PHARMACEUTICALS : Esmo late-breaking data show libtayo (cemiplimab) and chemothe..
AQ
09/20SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..
AQ
09/20Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar
DJ
09/20SANOFI : Regeneron, Sanofi Say Lung Cancer Drug Libtayo Improves Overall Patient Survival ..
MT
09/20SANOFI : Regeneron's Libtayo Combo Extends Lung Cancer Patients' Lives In Phase 3 Study
MT
09/17INSIDER SELL : Regeneron Pharmaceuticals
MT
09/16REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/16Regeneron Pharmaceuticals, Inc. Enters into Supply Agreement with Army Contracting Comm..
CI
09/15AFTER HOURS WATCH LIST SCORECARD : Yumc, regn, lyv,
MT
More news
News in other languages on REGENERON PHARMACEUTICALS
09/20Regeneron et Sanofi déclarent que le Libtayo, un médicament contre le cancer du poumon,..
09/20Les valeurs à suivre aujourd'hui à la Bourse de Paris Lundi 20 septembre 2021
09/20Les valeurs à suivre aujourd'hui à la Bourse de Paris Lundi 20 septembre 2021
09/20SANOFI : données encourageantes pour Libtayo contre le cancer du poumon
09/20Le combo Libtayo de Sanofi-Regeneron prolonge la vie des patients atteints de cancer du..
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Stock Trading Strategies
REGENERON PHARMACEUTICALS - 09/21
Technically solid
BUY
More Stock Trading Analysis
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 646,95 $
Average target price 681,41 $
Spread / Average Target 5,33%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS33.91%67 262
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
VERTEX PHARMACEUTICALS-21.38%48 202
BEIGENE, LTD.50.36%36 146